Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 4
Submit an article Journal homepage
1,080
Views
11
CrossRef citations to date
0
Altmetric
Diabetes

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

Lena Landstedt-HallinKarolinska Institutet, Department of Clinical Sciences, Division of Medicine, Danderyd Hospital, Stockholm, Sweden; Correspondence[email protected]
,
Jens GundgaardNovo Nordisk A/S, Søborg, Denmark;
,
Åsa EricssonNovo Nordisk Scandinavia AB, Malmö, Sweden
&
Susanne Ellfors-ZetterlundNovo Nordisk Scandinavia AB, Malmö, Sweden
Pages 647-655 | Received 07 Nov 2016, Accepted 23 Dec 2016, Published online: 20 Jan 2017

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Beatriz Rodriguez-Sanchez, Isaac Aranda-Reneo, Juan Oliva-Moreno & Julio Lopez-Bastida. (2021) Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review. ClinicoEconomics and Outcomes Research 13, pages 307-334.
Read now
Steffen Haldrup, Annunziata Lapolla, Jens Gundgaard & Michael L. Wolden. (2020) Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy. Journal of Medical Economics 23:3, pages 271-279.
Read now

Articles from other publishers (9)

Pierre Gourdy, Patrice Darmon, Isabelle Borget, Corinne Emery, Isabelle Bureau, Bruno Detournay, Amar Bahloul, Noemie Allali, Aymeric Mahieu & Alfred Penfornis. (2024) Basal Insulinotherapy in Patients Living with Diabetes in France: The EF-BI Study. Diabetes Therapy 15:6, pages 1349-1360.
Crossref
Tone Vonheim Madsen, John Graham Cooper, Siri Carlsen, Karianne Loevaas, Magne Rekdal, Jannicke Igland, Sverre Sandberg, Grethe Åstrøm Ueland, Marjolein Memelink Iversen & Una Sølvik. (2023) Intensified follow-up of patients with type 1 diabetes and poor glycaemic control: a multicentre quality improvement collaborative based on data from the Norwegian Diabetes Register for Adults. BMJ Open Quality 12:2, pages e002099.
Crossref
Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Value in Health 25:7, pages 1235-1252.
Crossref
Z. Kevin Lu, Xiaomo Xiong, Taiying Lee, Jun Wu, Jing Yuan & Bin Jiang. (2021) Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis. Frontiers in Pharmacology 12.
Crossref
Malin Sellbom & Charlotta Nilsson. (2021) Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes. Practical Diabetes 38:2, pages 13-19.
Crossref
V. Preumont & M. Buysschaert. (2020) Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials. Diabetes & Metabolism 46:2, pages 83-88.
Crossref
Monika Russel-Szymczyk, Vasil Valov, Alexandra Savova & Manoela Manova. (2019) Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria. BMC Endocrine Disorders 19:1.
Crossref
Marc Evans, Roopa Mehta, Jens Gundgaard & Barrie Chubb. (2018) Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Therapy 9:5, pages 1919-1930.
Crossref
Chantal Mathieu, Pieter Gillard & Katrien Benhalima. (2017) Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Reviews Endocrinology 13:7, pages 385-399.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.